Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

Fig. 2

Drug dose confirmation step (Step 1). A dose confirmation part was established as Step 1 based on the doses in the AXEPT Study (CAP: 1600 mg/m2, IRI: 200 mg/m2). Steering Committee (SC) will assess dose limiting toxicity (DLT) for each dose level of OX and IRI in Cycle 1 (before the start of Cycle 2) to determine the recommended doses (RDs). After RD review by the Efficacy and Safety Assessment Committee, SC will report upon approval by the Certified Review Board. CAP, capecitabine; BEV, bevacizumab; OX, oxaliplatin; IRI, irinotecan

Back to article page